Posted: October 30, 2024 at 2:42 am
Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients
Read the original here:
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Posted: October 30, 2024 at 2:42 am
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note (“Note”) issued on January 11, 2023.
Continue reading here:
Shuttle Pharma Pays Off Senior Secured Convertible Note
Posted: October 30, 2024 at 2:42 am
CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share.
See the article here:
BioVie Inc. Announces Closing of Registered Direct Offering
Posted: October 30, 2024 at 2:42 am
FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Continued here:
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Posted: October 30, 2024 at 2:42 am
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET
Read more:
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Posted: October 30, 2024 at 2:42 am
TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
Follow this link:
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
Posted: October 30, 2024 at 2:42 am
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes.
Excerpt from:
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Posted: October 30, 2024 at 2:42 am
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
See the original post here:
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Posted: October 30, 2024 at 2:42 am
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.
Read the rest here:
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
Posted: October 30, 2024 at 2:42 am
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.
See the original post:
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
